The natural history of the immune response to exogenous factor VIII in severe haemophilia A

Haemophilia

Volumn 4, Issue 4, 1998, Pages 546-551

  Scandella, D ^a,d   Mondorf, W ^b   Klinge, J ^c  

^a HOLLAND LABORATORY   (United States)

^b Spezialpraxis B   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d AMERICAN RED CROSS   (United States)

Author keywords

Antibody; Factor VIII; Haemophilia A; Immune response; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; CONFERENCE PAPER; DIAGNOSTIC VALUE; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOPRECIPITATION; PRIORITY JOURNAL; RELIABILITY;

EID: 0031830428     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440546.x     Document Type: Conference Paper

References (15)

1. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-42.
2. r-80,000 light chain. Eur J Biochem 1987; 166: 37-43.
3. Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
4. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucl Acids Res 1994; 22: 3511-33.
5. Hoyer LW, Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GCI, eds. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Inhibitors to Coagulation Factors. New York: Plenum Press, 1995; 35-45.
6. Gilles JGG, Arnout J, Vermylen J, Saint-Remy J-MR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
7. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70: 9-14.
8. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 27424-31.
9. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrhag 1975; 34: 869-72.
10. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemostas 1995; 73: 247-51.
11. 593 to Cys mutation. Blood 1997; 90: 1902-10.
12. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries J, Hurst D, Bray G, Scandella D. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 1997; 89: 3663-71.
13. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White III G, Lee M, et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
14. Prowse CV. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assessment. Thromb Haemostas 1995; 74: 1191-6.
15. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Brit J Haematol 1996; 93: 688-93.